tbuckley/cabot-search huggingface dataset:
Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma
Authors: Daniel D Joyce, Vidit Sharma, Kevin M Wymer, James P Moriarty, Bijan J Borah, Arman Walia, Brian A Costello, Lance C Pagliaro, Siamak Daneshmand, Bradley C Leibovich, Stephen A Boorjian
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background The Surgery in Early Metastatic Seminoma (SEMS) trial examined retroperitoneal lymph node dissection as first-line treatment for patients with isolated 1-3 cm retroperitoneal lymphadenopathy. To date, the standard of care for these patients has been either chemotherapy or radiotherapy. Herein, we evaluated the relative cost-effectiveness of these management strategies. Methods A microsimulation model assessed the cost-effectiveness of retroperitoneal lymph node dissection, chemotherapy, and radiotherapy for stage IIA seminoma. Sensitivity analyses were performed to evaluate model robustness. Retroperitoneal lymph node dissection recurrence probabilities were obtained from the SEMS trial. All other probability and utility values were obtained from published literature. Primary outcomes included costs from a commercial insurer’s perspective, effectiveness (quality adjusted life-years [QALYs]), and incremental cost-effectiveness ratios using a willingness-to-pay threshold of $100 000/QALY. Results At a lifetime horizon, the mean costs per patient for retroperitoneal lymph node dissection, radiotherapy, and chemotherapy were $58 469, $98 783, and $104 096, and the mean QALYs were 40.61, 40.70, and 39.15, respectively. Retroperitoneal lymph node dissection was found to be the most cost-effective approach because of high costs and accrued disutility of chronic toxicities associated with radiotherapy (cost-effectiveness ratios = $433 845/QALY) and chemotherapy (dominated). On 1-way sensitivity analyses, retroperitoneal lymph node dissection was no longer cost-effective if the probabilities of infertility and cardiovascular toxicity after radiotherapy were less than 13% and 16%, respectively, or if the 2-year probability of progression after retroperitoneal lymph node dissection was more than 26%. Conclusions Retroperitoneal lymph node dissection was the most cost-effective treatment approach for stage IIA seminoma. These findings support clinical guideline consideration of including retroperitoneal lymph node dissection as a treatment option for well-selected patients with stage IIA seminoma.
Chromosomal Gains as a Favorable Prognostic Factor in Pediatric ALL
Authors: Kajsa Paulsson
Journal: Journal of Clinical Oncology (2023)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL. September 20, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01760 Journal of Clinical Oncology - published online before print October 11, 2023 PMID: 37820292 Chromosomal Gains as a Favorable Prognostic Factor in Pediatric ALL Kajsa Paulsson , PhD1xKajsa PaulssonSearch for articles by this author Show More 1Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden https://doi.org/10.1200/JCO.23.01760 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by the Swedish Childhood Cancer Fund, grant number PR2021-0016; the Swedish Cancer Fund, grant number 22-2062-Pj; Governmental Funding of Clinical Research within the National Health Service Sweden; the Swedish Research Council, grant number 2020-00997; and Ellen Bachrach's Memorial Fund.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTChromosomal Gains as a Favorable Prognostic Factor in Pediatric ALLThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported. Companion Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL
Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations
Authors: Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masakatsu Tsurusaki, Takuya Nakai, Michiie Sakamoto, Kazuto Nishio, Masatoshi Kudo
Journal: Liver Cancer (2023)

&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype, their role on TME remains controversial. We aimed to clarify the heterogeneity of immunophenotype in HCC with Wnt/β-catenin mutations. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; This study includes 152 resected HCCs; mutations in the &lt;i&gt;catenin beta-1&lt;/i&gt;, &lt;i&gt;adenomatous polyposis coli,&lt;/i&gt; or &lt;i&gt;AXIN1&lt;/i&gt;, or &lt;i&gt;AXIN2&lt;/i&gt; genes were defined as Wnt/β-catenin mutations. With hierarchical cluster analyses, TME was classified into inflamed or non-inflamed classes based on the gene expressions associated with T-cell activation. Expression profiles of molecules related to cell differentiation and biliary-stem cell markers were compared between the TME classes to investigate whether differences in tumor traits were associated with TME. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Forty of 152 (26.3%) HCCs carried the Wnt/β-catenin mutations. Of these, 33 were classified as non-inflamed (33/40, 82.5%) and 7 as inflamed (7/40, 17.5%). Non-inflamed class was characterized by low number of CD3+, CD4+, and CD8+ cells on immunostaining, and high mRNA expressions of &lt;i&gt;AXIN2 and GLUL,&lt;/i&gt; which are involved in the canonical Wnt/β-catenin signaling and hepatocyte differentiation, respectively. Non-inflamed tumors showed higher enhancement on the hepatobiliary-phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) compared to inflamed tumors. HCCs classified as inflamed class are revealed to have high numbers of CD3+, CD4+, and CD8+ tumor infiltrating lymphocytes on immunostaining. This class is associated with increased expression of anti-epithelial cell adhesion molecule and FOXM1 accompanied by upregulation of genes related to interferon-gamma signaling, dendritic cell migration, regulatory T cells, and myeloid-derived suppressor cell activation and recognized as low enhancement nodule on Gd-EOB-DTPA-enhanced MRI. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; Heterogeneity of tumor traits and TME was observed in HCC with Wnt/β-catenin mutation. The potential was indicated that tumor traits and TME are determined not only by the activation of the &lt;i&gt;HNF4A&lt;/i&gt; but also by &lt;i&gt;FOXM1&lt;/i&gt;, both of which are downstream transcription factor of the Wnt/β-catenin signaling pathway.
Case 31-2023: A 79-Year-Old Man with Involuntary Movements and Unresponsiveness
Authors: Albert Y. Hung, Rajiv Gupta, Scott B. Silverman, Caroline F. Hilburn
Journal: New England Journal of Medicine (2023)

A 79-year-old man was admitted because of involuntary movements on the left side and transient unresponsiveness. Episodes of involuntary movements had started 9 months earlier. A diagnosis was made.
Tuberculous Meningitis — New Approaches Needed
Authors: Sean Wasserman, Thomas S. Harrison
Journal: New England Journal of Medicine (2023)

The clinical effects of infectious diseases are determined by a complex interplay between pathogen and immune response, a dynamic exemplified by tuberculous meningitis. Despite being paucibacillary, tuberculous meningitis causes permanent neurologic injury and death in a high proportion of affected persons through local inflammatory complications and stroke. The maladaptive inflammatory response in tuberculous meningitis has not been fully characterized but may be amenable to modulation by glucocorticoids. A trial conducted 20 years ago changed practice by showing that dexamethasone reduced mortality among patients with tuberculous meningitis in Vietnam.1 This is the only intervention for tuberculous meningitis supported by strong evidence . . .
Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline
Authors: Humera Khurshid, Nofisat Ismaila, Jessica Bian, Raetasha Dabney, Millie Das, Peter Ellis, Jill Feldman, Christine Hann, Swati Kulkarni, Janessa Laskin, Rami Manochakian, Deebya Raj Mishra, Isabel Preeshagul, Pavan Reddy, Ashish Saxena, Frank Weinberg, Gregory P. Kalemkerian
Journal: Journal of Clinical Oncology (2023)

To provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2022. Outcomes of interest included response rates, overall survival, disease-free survival or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. The literature search identified 95 relevant studies to inform the evidence base for this guideline. Evidence-based recommendations were developed to address systemic therapy options, timing of therapy, treatment in patients who are older or with poor performance status, role of biomarkers, and use of myeloid-supporting agents in patients with small-cell lung cancer.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study
Authors: Bertrand Tombal, Sean Collins, Alicia K. Morgans, Elke Hunsche, Bruce Brown, Emily Zhu, Alberto Bossi, Neal Shore
Journal: European Urology (2023)

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated testosterone suppression to castrate levels in men with advanced prostate cancer (PCa) in the HERO study. Since advanced PCa and its treatments can impact patients' daily life, it is imperative to understand the impact of systemic therapy on patient health-related quality of life (HRQOL). To report the HRQOL for patients on relugolix compared with those on leuprolide in on-treatment and testosterone recovery periods of the HERO study. A phase 3 randomized controlled study was conducted in 934 patients with advanced PCa. Patients underwent 2:1 randomization and received relugolix 120 mg orally once daily or leuprolide 3-mo injections for 48 wk. Testosterone recovery was evaluated in a patient subset. HRQOL evaluations were based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) and the Prostate Cancer Module (EORTC QLQ-PR25) during treatment and testosterone recovery phases. In a post hoc analysis, predictors of HRQOL deterioration were evaluated. No statistically significant differences between the two groups were found in changes from baseline to the end of treatment in either the EORTC QLQ-C30 or the EORTC QLQ-PR25 instrument. During the testosterone recovery phase, hormonal treatment–related symptoms scores were lower for relugolix than for leuprolide, suggesting a lower burden of hormone-related symptoms associated with a treatment that has more rapid testosterone recovery after treatment cessation. Limitations include low patient numbers in the testosterone recovery group. Oral relugolix is a therapeutic option with similar patient-reported HRQOL to leuprolide, providing an oral option for androgen deprivation therapy associated with a more rapid testosterone reduction. In men with advanced prostate cancer, relugolix had similar health-related quality of life to leuprolide.
Comparison of advanced echocardiographic right ventricular functional parameters with cardiovascular magnetic resonance in adult congenital heart disease
Authors: Daniel J Bowen, Robert M Kauling, Chiara Pelosi, Lourus van Haveren, Jackie S McGhie, Judith A A E Cuypers, Alexander Hirsch, Jolien W Roos-Hesselink, Annemien E van den Bosch
Journal:  (2023)

Abstract Aims Advanced transthoracic echocardiography (TTE) using volumetric and deformational indices provides detailed quantification of right ventricular (RV) function in adults with congenital heart disease (ACHD). Two-dimensional multi-plane echocardiography (2D-MPE) has demonstrated regional wall differences in RV longitudinal strain (LS). This study aims to evaluate the association of these parameters with cardiovascular magnetic resonance (CMR). Methods and results One-hundred stable ACHD patients with primarily affected RVs were included (age 50 ± 5 years; 53% male). Conventional and advanced echocardiographic RV functional parameters were compared with CMR-derived RV function. Advanced echocardiographic RV functional parameters were measurable in approximately one-half of the study cohort, while multi-wall LS assessment feasibility was lower. CMR RV ejection fraction (CMR-RVEF) was moderately correlated with deformational, area, and volumetric parameters [RV global LS (lateral wall and septum), n = 55: r = −0.62, P &amp;lt; 0.001; RV wall average LS, n = 34: r = −0.49, P = 0.002; RV lateral wall LS, n = 56: r = −0.45, P &amp;lt; 0.001; fractional area change, n = 67: r = 0.48, P &amp;lt; 0.001; 3D-RVEF, n = 48: r = 0.40, P = 0.005]. Conventional measurements such as TAPSE and RV S′ correlated poorly. RV global LS best identified CMR-RVEF &amp;lt; 45% (area under the curve: 0.84, P &amp;lt; 0.001: cut-off value −19%: sensitivity 100%, specificity 57%). RVEF and LS values were significantly higher when measured by CMR compared with TTE (mean difference RVEF: 5 [−9 to 18] %; lateral (free) wall LS: −7 [7 to −21] %; RV global LS: −6 [5 to −16] %) while there was no association between respective LS values. Conclusion In ACHD patients, advanced echocardiographic RV functional parameters are moderately correlated with CMR-RVEF, although significant differences exist between indices measurable by both modalities.
Potential role of cross-education in early-stage rehabilitation after anterior cruciate ligament reconstruction
Authors: Justin W Andrushko, Joshua C Carr, Jonathan P Farthing, Lindsey K Lepley, Jason M DeFreitas, Stuart Goodall, Ashlee M Hendy, Glyn Howatson, Dustin R Grooms, Tjerk Zult, Tibor Hortobagyi, Gulcan Harput, Maria Papandreou, Kazunori Nosaka, Richard G Carson, Andrea Manca, Franca Deriu, David George Behm, Dawson J Kidgell, Nicholas C Clark, Lara A Boyd
Journal: British Journal of Sports Medicine (2023)
Mitochondrial Respiration and Exercise Performance in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Huda Abu-Own, Olaf Wendler, Darlington O. Okonko
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
What Goes into Patient Selection for Lung Cancer Screening? Factors Associated with Clinician Judgments of Suitability for Screening
Authors: Eduardo R. Núñez, Sanqian Zhang, Mark E. Glickman, Shirley X. Qian, Jacqueline H. Boudreau, Peter K. Lindenauer, Christopher G. Slatore, Donald R. Miller, Tanner J. Caverly, Renda Soylemez Wiener
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Achieving the net benefit of lung cancer screening (LCS) depends on optimizing patient selection.
Twisted: Escape of epitope-edited healthy cells from immune attack
Authors: Laura Volta, Markus G. Manz
Journal: The Journal of Experimental Medicine (2023)

Hematopoietic stem and progenitor cell-derived neoplasia is challenging to target by cell surface-directed immunotherapy due to lack of tumor cell-specific antigen identification. Marone et al. (2023. J. Exp. Med.https://doi.org/10.1084/jem.20231235) provide a solution by target-epitope resistance editing in healthy hematopoietic stem cells.
Prevalence and course of pregnancy symptoms using self-reported pregnancy app symptom tracker data
Authors: Michael Nissen, Nuria Barrios Campo, Madeleine Flaucher, Katharina M. Jaeger, Adriana Titzmann, Dominik Blunck, Peter A. Fasching, Victoria Engelhardt, Bjoern M. Eskofier, Heike Leutheuser
Journal: npj Digital Medicine (2023)

During pregnancy, almost all women experience pregnancy-related symptoms. The relationship between symptoms and their association with pregnancy outcomes is not well understood. Many pregnancy apps allow pregnant women to track their symptoms. To date, the resulting data are primarily used from a commercial rather than a scientific perspective. In this work, we aim to examine symptom occurrence, course, and their correlation throughout pregnancy. Self-reported app data of a pregnancy symptom tracker is used. In this context, we present methods to handle noisy real-world app data from commercial applications to understand the trajectory of user and patient-reported data. We report real-world evidence from patient-reported outcomes that exceeds previous works: 1,549,186 tracked symptoms from 183,732 users of a smartphone pregnancy app symptom tracker are analyzed. The majority of users track symptoms on a single day. These data are generalizable to those users who use the tracker for at least 5 months. Week-by-week symptom report data are presented for each symptom. There are few or conflicting reports in the literature on the course of diarrhea, fatigue, headache, heartburn, and sleep problems. A peak in fatigue in the first trimester, a peak in headache reports around gestation week 15, and a steady increase in the reports of sleeping difficulty throughout pregnancy are found. Our work highlights the potential of secondary use of industry data. It reveals and clarifies several previously unknown or disputed symptom trajectories and relationships. Collaboration between academia and industry can help generate new scientific knowledge.
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
Authors: Keyuan Zhang, Xiang Zhang, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Suning Chen, Aining Sun, Yanming Zhang, Depei Wu, Ying Wang
Journal: Blood Cancer Journal (2023)
Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases
Authors: Sachi Khemka, Aananya Reddy, Ricardo Isaiah Garcia, Micheal Jacobs, Ruhananhad P. Reddy, Aryan Kia Roghani, Vasanthkumar Pattoor, Tanisha Basu, Ujala Sehar, P. Hemachandra Reddy
Journal: Ageing Research Reviews (2023)
Ultrasound guided lavage with corticosteroid injection versus sham lavage with and without corticosteroid injection for calcific tendinopathy of shoulder: randomised double blinded multi-arm study
Authors: Stefan Moosmayer, Ole Marius Ekeberg, Hanna Björnsson Hallgren, Ingar Heier, Synnøve Kvalheim, Niels Gunnar Juel, Jesper Blomquist, Are Hugo Pripp, Jens Ivar Brox
Journal: BMJ (2023)

To compare treatment effects between ultrasound guided lavage with corticosteroid injection and sham lavage with and without corticosteroid injection in patients with calcific tendinopathy of the shoulder.Pragmatic, three arm, parallel group, double blinded, sham controlled, randomised, superiority trial with repeated measurements over 24 months.Six hospitals in Norway and Sweden.220 adults with calcific tendinopathy of the shoulder, persistent for at least three months.Ultrasound guided deposit lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (lavage+steroid); sham lavage plus subacromial injection of 20 mg triamcinolone acetonide and 9 mL 1% lidocaine hydrochloride (sham lavage+steroid); or sham lavage plus subacromial injection of 10 mL 1% lidocaine hydrochloride (sham). All patients received a physiotherapeutic treatment regimen consisting of four home exercises.The primary outcome was the result on the 48 point scale (0=worst; 48=best) of the Oxford Shoulder Score (OSS) at four month follow-up. Secondary outcomes included measurements on the short form of the Disabilities of the Arm, Shoulder and Hand questionnaire (QuickDASH) and of pain intensity up to 24 months. The influence of the size of the deposit at baseline and of the persistence or disappearance of the deposit was investigated.Data from 218 (99%) participants were included in the primary analysis. Differences between groups on the OSS at four months were not significant: lavage+steroid versus sham 0.2 (95% confidence interval -2.3 to 2.8; P=1.0); sham lavage+steroid versus sham 2.0 (-0.5 to 4.6; P=0.35); lavage+steroid versus sham lavage+steroid -1.8 (-4.3 to 0.7; P=0.47). After four months, 143 patients with insufficient treatment effect received supplementary treatment. At 24 months, none of the study procedures was superior to sham. No serious adverse events were reported.This study found no benefit for ultrasound guided lavage with a corticosteroid injection or for sham lavage with a corticosteroid injection compared with sham treatment in patients with calcific rotator cuff tendinopathy of the shoulder.NCT02419040EudraCT 2015-002343-34; Ethical committee Norway 2015-002343-34; Ethical committee Sweden 2015/79-31; Clinicaltrials.gov NCT02419040.
The role of microRNAs in the pathophysiology of human central nervous system: A focus on neurodegenerative diseases
Authors: Delsuz Rezaee, Fatemeh Saadatpour, Nayyereh Akbari, Anahita Zoghi, Sajad Najafi, Parisa Beyranvand, Fahimeh Zamani-Rarani, Mohammad Amin Rashidi, Saeid Bagheri-Mohammadi, Mohammad Bakhtiari
Journal: Ageing Research Reviews (2023)